Keller Karsten, Stelzer Kathrin, Ostad Mir Abolfazl, Post Felix
Center for Thrombosis and Hemostasis, University Medical Center Mainz (Johannes Gutenberg-University Mainz), Mainz, Germany; Center for Cardiology, Department of Cardiology I, University Medical Center Mainz (Johannes Gutenberg-University Mainz), Mainz, Germany; Team Doctor of the German Bundesliga Club, 1. FSV Mainz 05 in the Soccer Season 2014/2015, Mainz, Germany.
Center for Cardiology, Department of Cardiology I, University Medical Center Mainz (Johannes Gutenberg-University Mainz), Mainz, Germany; Team Doctor of the German Bundesliga Club, 1. FSV Mainz 05 in the Soccer Season 2014/2015, Mainz, Germany.
Adv Med Sci. 2017 Sep;62(2):317-329. doi: 10.1016/j.advms.2016.11.010. Epub 2017 May 13.
Arterial hypertension (aHT) is the leading risk factor for morbidity and mortality worldwide. Blood pressure (BP) deviation at rest is well defined and accompanies risk for cardiovascular events and cardiovascular mortality. A growing body of evidence emphasises that an exaggerated blood pressure response (EBPR) in cardiopulmonary exercise testing (CPET) could help to identify seemingly cardiovascular healthy and normotensive subjects, who have an increased risk of developing aHT and cardiovascular events in the future.
The PubMed online database was searched for published studies reporting exercise-related BP and both the risk of aHT and cardiovascular events in the future.
We identified 18 original studies about EBPR in CPET, which included a total of 35,151 normotensive individuals for prediction of new onset of aHT in the future and 11 original studies with 43,012 enrolled subjects with the endpoint of cardiovascular events in the future. Although an EBPR under CPET is not well defined, a large number of studies emphasise that EBPR in CPET is associated with both new-onset aHT and cardiovascular events in the future.
A growing number of studies support the hypothesis that EBPR in CPET may be a diagnostic tool to identify subjects with an elevated risk of developing aHT and cardiovascular events in the future.
动脉高血压(aHT)是全球发病和死亡的主要危险因素。静息血压(BP)偏差已得到明确界定,并伴随着心血管事件和心血管死亡风险。越来越多的证据强调,心肺运动试验(CPET)中过度的血压反应(EBPR)有助于识别看似心血管健康且血压正常的受试者,这些人未来患aHT和心血管事件的风险会增加。
在PubMed在线数据库中搜索已发表的研究,这些研究报告了与运动相关的血压以及未来患aHT和心血管事件的风险。
我们确定了18项关于CPET中EBPR的原始研究,其中共有35151名血压正常个体用于预测未来aHT的新发情况,以及11项原始研究,涉及43012名受试者,其终点为未来的心血管事件。尽管CPET中的EBPR尚未得到明确界定,但大量研究强调CPET中的EBPR与未来新发aHT和心血管事件均相关。
越来越多的研究支持这一假设,即CPET中的EBPR可能是一种诊断工具,用于识别未来患aHT和心血管事件风险升高的受试者。